Carmen J Williams, MD | |
111 T.w. Alexander Drive, Nih/niehs Cru Building 109, Research Triangle Park, NC 27709 | |
(919) 541-9899 | |
(919) 541-9854 |
Full Name | Carmen J Williams |
---|---|
Gender | Female |
Speciality | Obstetrics & Gynecology |
Location | 111 T.w. Alexander Drive, Research Triangle Park, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134157274 | NPI | - | NPPES |
0017920230007 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | MD041090E (Pennsylvania) | Secondary |
207V00000X | Obstetrics & Gynecology | 2008-01487 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Carmen J Williams, MD Po Box 12233, Md E4-05, Research Triangle Park, NC 27709-2233 Ph: (919) 541-2158 | Carmen J Williams, MD 111 T.w. Alexander Drive, Nih/niehs Cru Building 109, Research Triangle Park, NC 27709 Ph: (919) 541-9899 |
News Archive
PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.
Endologix, Inc. developer of minimally invasive treatments for aortic disorders, announced today the first clinical implant of the Company's Ventana fenestrated stent graft at Auckland City Hospital in Auckland, New Zealand.
BMJ News reports on South African Health Minister Aaron Motsoaledi's visit to the U.S. last week, where he spoke at a forum in Washington, D.C., on the efforts the government is making to promote HIV prevention and treatment and improve the country's health system. The publication notes that the health ministry has set a goal of testing the HIV status of 15 million people in the country by the end of the year - "nearly a third of its population of 50 million."
Yesterday, the European Patent Office (EPO) revoked previously granted claims of Cellectis' European Patent No. EP 1485475 during an oral hearing in an opposition proceeding initiated by Precision BioSciences. As a result of the opposition, Cellectis' previously granted claims to single-chain meganucleases, including those derived from I-CreI, were revoked in their entirety. Claims to hybrid meganucleases were cancelled or severely restricted.
› Verified 4 days ago